comparemela.com
Home
Live Updates
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results : comparemela.com
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022
Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022
Year-end 2023 cash,...
Related Keywords
Derek Maetzold
,
Castle Biosciences
,
Nasdaq
,
Facebook
,
Castle Biosciences Inc
,
Instagram
,
Linkedin
,
Unaudited Fourth Quarter Ended
,
Path Melanoma
,
Unaudited Year Ended
,
Cypher Barrett
,
Cash Equivalents
,
Marketable Investment
,
Mypath Melanoma
,
Markets
,
comparemela.com © 2020. All Rights Reserved.